Core Insights - Johnson & Johnson announced promising results from the Phase 3 ICONIC-LEAD study, which is the first registrational study assessing the safety and efficacy of icotrokinra in treating moderate-to-severe plaque psoriasis in both adolescents and adults simultaneously [1][2] Group 1: Study Results - 84.1% of adolescents treated with icotrokinra achieved an Investigator's Global Assessment (IGA) score of 0/1 (clear or almost clear skin) at Week 16, compared to 27.3% in the placebo group [2] - At Week 24, the efficacy improved further, with 86.4% achieving IGA 0/1 and 88.6% achieving a Psoriasis Area and Severity Index (PASI) 90 response [2] - 75% of adolescents achieved completely clear skin (IGA 0) and 63.6% achieved PASI 100 at Week 24 [2] Group 2: Safety Profile - The safety profile of icotrokinra was favorable, with 50% of adolescents experiencing at least one adverse event (AE) compared to 73% in the placebo group at Week 16, with no new safety signals identified [2] Group 3: Product Information - Icotrokinra is a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, which is crucial in the inflammatory response associated with moderate-to-severe plaque psoriasis [8] - The drug is part of the ICONIC clinical development program, which includes multiple studies evaluating its efficacy and safety in various populations [6][8]